Phase 4Enrolling by invitationINTERVENTIONAL
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
ClinicalTrials.gov · NCT07057310 · Registry updated: 2026-07-20
- Condition / research focus
- Obesity; Menopause
- Sponsor
- Mayo Clinic
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2025-05-01. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- semaglutide or tirzepatide (drug)
- Lifestyle modification intervention (behavioral)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Mayo Clinic in Florida
Jacksonville, Florida, United States
Site recruitment: Not reported